Navigation Links
Angiotech Pharmaceuticals Announces Conference Call and Webcast
Date:6/24/2010

Second Quarter 2010 Financial Results

VANCOUVER, June 24 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) will host a conference call discussing its financial results for the second quarter ended June 30, 2010, on Friday, July 30, 2010 at 11:00 AM ET (8:00 AM PT).

Dial-in information for the earnings call on July 30, 2010 is as follows:

    North America (toll-free): (866) 277-1182
    International: (617) 597-5359
    Enter Passcode: 18173223

A live webcast of the earnings call will be available to interested parties through Angiotech's website at www.angiotech.com in the Investors section.

A press release announcing Angiotech's financial results will be issued prior to the call on July 30th at approximately 8:00 AM ET (5:00 AM PT).

An archived replay of the call will be available until August 6, 2010.

Replay information is as follows:

    North America (toll-free): (888) 286-8010
    International: (617) 801-6888
    Enter Passcode: 33507758

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at www.angiotech.com.


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Angiotech announces exclusive distribution agreement with B. Braun for Angiotechs proprietary Quill(TM) SRS product line
2. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
3. Angiotech Pharmaceuticals Announces Conference Call and Webcast
4. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
5. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
6. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
7. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
8. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
9. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
10. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
11. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , ... February 22, 2017 , ... ... is has acquired Kendall Research Systems, LLC (KRS) clinical development program. ... develops neural interface technology for research and clinical applications. The terms of the ...
(Date:2/22/2017)... 22, 2017 Scientists propose in Nature ... damage in Gaucher and maybe other lysosomal storage diseases ... costs than current therapies. An international research ... , which also included investigators from the University of ... data Feb. 22. The study was conducted in mouse ...
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots ... scientists from around the world, is pleased to announce the 2nd annual Precision ... 2017. This premier, online-only conference focused on the development and advancements in precision ...
(Date:2/22/2017)... , Feb. 22, 2017 Origin (Origin Agritech, LLC, ... trait and seed provider, and Arcadia (Arcadia ... that develops and commercializes agricultural productivity traits and nutritional products, today ... corn biotechnology product developed in China to ... regulatory trials. ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
(Date:2/2/2017)... -- Central to its deep commitment to honor the ... Prize Foundation today announced the laureates of the ... in their respective fields of Life Sciences and ... recognized with the 2017 Japan Prize for original ... the advancement of science and technology, but also ...
(Date:1/31/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded ... bacterial infections, today announced it has acquired a ... Bono Bio Ltd (PBB) to bolster its pipeline ... of Gram-negative bacteria.   The assets acquired have been ... group company. "The acquisition of these ...
Breaking Biology News(10 mins):